SCHEMBL5574030

SCHEMBL5574030

COc1cc(-c2cc(C(=O)N3CCC(CC(CC4CCN(C(=O)c5ccc(C)c(-c6cc(OC)c(OC)c(OC)c6)c5)CC4)N(C)C)CC3)ccc2C)cc(OC)c1OC

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 1/20 0.42
KCNH2 Q12809 1/20 0.41
CYP1A2 P05177 1/20 0.41
HSD11B1 P28845 4/20 0.41
FASN P49327 2/20 0.41
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5574064 0.99 ALDH1A1 (0.42) ALDH1A1L3MBTL1GAAKCNH2CYP1A2
SCHEMBL5574086 0.87 POLB (0.49) ALDH1A1L3MBTL1GAAKCNH2CYP1A2
Hydrochloric Acid SCHEMBL5570683 0.86 POLB (0.48) ALDH1A1L3MBTL1GAAKCNH2CYP1A2
SCHEMBL6785283 0.79 ALDH1A1 (0.56) ALDH1A1L3MBTL1GAACYP1A2LMNA
SCHEMBL5573189 0.77 POLB (0.48) ALDH1A1L3MBTL1GAAKCNH2CYP1A2
SCHEMBL5569592 0.76 POLB (0.53) ALDH1A1L3MBTL1GAACYP1A2LMNA
Hydrochloric Acid SCHEMBL5573076 0.76 POLB (0.48) ALDH1A1L3MBTL1GAAKCNH2CYP1A2
Hydrochloric Acid SCHEMBL5570630 0.75 POLB (0.52) ALDH1A1L3MBTL1GAACYP1A2LMNA
SCHEMBL5569603 0.75 ALDH1A1 (0.44) ALDH1A1L3MBTL1GAACYP1A2HTT
SCHEMBL5573131 0.74 ALDH1A1 (0.52) ALDH1A1L3MBTL1GAACYP1A2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 ALDH1A1 2028/4885L3MBTL1 1633/4885GAA 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.